Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALIMERA SCIENCES INCALIM · Entity 11664 | Chairman Emeritus | August 01, 2023 | August 03, 2023 |
| KALA BIO, Inc.KALA · Entity 7964 | Director | June 15, 2025 | June 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALIMERA SCIENCES INC
Report date August 01, 2023 · Filed August 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.26 · Expires 2033-07-31 | Direct | 6,000 |
Reported balance
After 2023-08-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-01 · Grant · Acquired 6,000 · Balance 6,000 F1: Vests in full on the date of the Issuer's annual meeting of stockholders in 2024 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in full on the date of the Issuer's annual meeting of stockholders in 2024 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date.
KALA BIO, Inc.
Report date June 15, 2025 · Filed June 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,374 |
Reported balance
After 2025-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-15 · Grant · Acquired 2,450 · Balance 10,374 F1: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. F2: Includes 4,973 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2035-06-14 | Direct | 5,450 |
Reported balance
After 2025-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-15 · Grant · Acquired 5,450 · Balance 5,450 F3: This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.
F2: Includes 4,973 unvested RSUs.
F3: This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2025 Filed Jun 17, 2025 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 5,450 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001415889-25-017612 · form4-06172025_080603.xml · derivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,450 Underlying: Common Stock · 5,450 shares Expires 2035-06-14 F3 · derivative.exercise_date: This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017612 · form4-06172025_080603.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,374 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. F2 · balance_after: Includes 4,973 unvested RSUs. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 3,150 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001415889-24-016571 · form4-06122024_080607.xml · derivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,150 Underlying: Common Stock · 3,150 shares Expires 2034-06-10 F3 · derivative.exercise_date: This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016571 · form4-06122024_080607.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,924 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024. F2 · balance_after: Includes 6,603 unvested RSUs. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:23 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0000950170-23-038054 · ownership.xml · derivative · entry 1 Myers C. Daniel · CIK 0001489533 · Chairman Emeritus 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2033-07-31 F1 · derivative.exercise_date: Vests in full on the date of the Issuer's annual meeting of stockholders in 2024 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001415889-23-010289 · form4-06232023_080621.xml · derivative · entry 4 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2033-06-21 F6 · derivative.exercise_date: This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 5,046 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001415889-23-010289 · form4-06232023_080621.xml · derivative · entry 3 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,046 Underlying: Common Stock · 5,046 shares Expires 2033-06-21 F5 · derivative.exercise_date: This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010289 · form4-06232023_080621.xml · nonDerivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,524 F3 · security: Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023. F4 · balance_after: Includes 6,524 unvested RSUs. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 3,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010289 · form4-06232023_080621.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,424 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026. F2 · balance_after: Includes 5,424 unvested RSUs. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | Disposition to issuerStock Option (right to buy) · Derivative | 800 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0001415889-23-009141 · form4-06022023_080636.xml · derivative · entry 3 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800 shares Expires 2032-06-15 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 443 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,197 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The cancelled option was granted on June 16, 2022 and provided for vesting as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | Disposition to issuerStock Option (right to buy) · Derivative | 840 | Not disclosed Strike: $110.50 | Not disclosed |
DisclosureSEC source: 0001415889-23-009141 · form4-06022023_080636.xml · derivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 840 shares Expires 2031-10-14 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 443 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,197 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The cancelled option was granted on October 15, 2021 and provided for vesting with respect to 1/3rd of the shares underlying the option on October 15, 2022 and as to an additional 1/36th of the shares underlying the option at the end of each successive one-month period thereafter until October 15, 2024. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 1,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-009141 · form4-06022023_080636.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,640 F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 443 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,197 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 1,640 unvested RSUs. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 17:16 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001474506-23-000010 · primary_doc.xml · derivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: Vests in full on the date of the Issuer's annual meeting of stockholders in 2023 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 16:46 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-22-006754 · form4-06172022_040632.xml · derivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 20:18 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantCommon Stock · Derivative | 6,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001474506-21-000161 · primary_doc.xml · derivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-11-01 F1 · derivative.exercise_date: Vests in full on June 15, 2022, provided the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 16:08 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001415889-21-004907 · form4-10192021_011033.xml · derivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2031-10-14 F1 · derivative.exercise_date: This option was granted on October 15, 2021 and vests with respect to 1/3rd of the shares underlying the option on October 15, 2022 and as to an additional 1/36th of the shares underlying the option at the end of each successive one-month period thereafter until October 15, 2024. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 16:25 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | SaleCommon Stock | 5,000 | $6.73 | $33,650.00 |
DisclosureSEC source: 0001474506-20-000239 · primary_doc.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,578 F1 · balance_after: On November 14, 2019, after the close of business, the issuer effected a one-for-15 reverse stock split, which is reflected in the amount shown in column 5. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 16:25 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001267602-20-000097 · wf-form4_159285750598570.xml · derivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2030-06-17 F1 · derivative.exercise_date: Vests in equal monthly installments over 12 months starting one month after the grant date (June 18, 2020), provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 16:26 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001267602-19-000092 · wf-form4_156106236739443.xml · derivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: Vests in equal monthly installments over 12 months starting one month after the grant date (June 19, 2019), provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 16:35 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Tax withholdingCommon Stock | 21,966 | $0.98 | $21,471.77 |
DisclosureSEC source: 0001267602-19-000035 · wf-form4_154948892544724.xml · nonDerivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,676 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of Restricted Stock Units. Such sale was executed pursuant to the mandatory terms of the Issuer's restricted stock unit award agreement that are intended to permit such sale to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to comply with the requirements of Rule 10b5-1(c). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 16:35 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Tax withholdingCommon Stock | 21,966 | $0.94 | $20,648.04 |
DisclosureSEC source: 0001267602-19-000035 · wf-form4_154948892544724.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,642 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of Restricted Stock Units. Such sale was executed pursuant to the mandatory terms of the Issuer's restricted stock unit award agreement that are intended to permit such sale to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to comply with the requirements of Rule 10b5-1(c). Read SEC document |
| January 22, 2018 Filed Jan 25, 2018 16:44 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 395,000 | $1.16 Strike: $1.16 | $458,200.00 |
DisclosureSEC source: 0001267602-18-000037 · wf-form4_151691667182921.xml · derivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,000 Underlying: Common Stock · 395,000 shares Expires 2028-01-21 F2 · derivative.exercise_date: This option shall vest in forty-eight equal monthly installments beginning on January 22, 2018, provided that the Reporting Person remains continuously employed by the Issuer through each vesting period. Read SEC document |
| January 22, 2018 Filed Jan 25, 2018 16:44 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantCommon Stock | 124,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001267602-18-000037 · wf-form4_151691667182921.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,161 F1 · shares: Represents shares of common stock underlying a restricted stock unit award (RSU). The RSU shall vest in two equal daily installments beginning on February 4, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| January 19, 2018 Filed Jan 19, 2018 16:40 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | SaleCommon Stock | 26,450 | $1.18 | $31,216.29 |
DisclosureSEC source: 0001267602-18-000027 · wf-form4_151639801630376.xml · nonDerivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,061 F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 Trading Plan dated August 11, 2017. Read SEC document |
| January 18, 2018 Filed Jan 19, 2018 16:40 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | SaleCommon Stock | 26,450 | $1.22 | $32,163.20 |
DisclosureSEC source: 0001267602-18-000027 · wf-form4_151639801630376.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,511 F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 Trading Plan dated August 11, 2017. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 16:53 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | SaleCommon Stock | 26,450 | $1.23 | $32,559.95 |
DisclosureSEC source: 0001267602-18-000014 · wf-form4_151631240674770.xml · nonDerivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,961 F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 Trading Plan dated August 11, 2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 16:53 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | SaleCommon Stock | 26,450 | $1.24 | $32,734.52 |
DisclosureSEC source: 0001267602-18-000014 · wf-form4_151631240674770.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,411 F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 Trading Plan dated August 11, 2017. Read SEC document |
| October 31, 2017 Filed Feb 8, 2018 18:52 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantCommon Stock | 2,494 | $1.05 | $2,607.48 |
DisclosureSEC source: 0001267602-18-000039 · wf-form5_151813394501045.xml · nonDerivative · entry 5 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,608 F1 · kind: These shares were acquired under the Alimera Sciences, Inc. 2010 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| April 28, 2017 Filed Feb 8, 2018 18:52 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantCommon Stock | 2,453 | $1.06 | $2,606.31 |
DisclosureSEC source: 0001267602-18-000039 · wf-form5_151813394501045.xml · nonDerivative · entry 4 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,114 F1 · kind: These shares were acquired under the Alimera Sciences, Inc. 2010 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 16:56 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | SaleCommon Stock | 21,172 | $1.39 | $29,429.08 |
DisclosureSEC source: 0001267602-17-000023 · wf-form4_148943857598840.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,861 Read SEC document |
| February 15, 2017 Filed Feb 8, 2018 18:52 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001267602-18-000039 · wf-form5_151813394501045.xml · nonDerivative · entry 3 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,661 Read SEC document |
| February 15, 2017 Filed Feb 8, 2018 18:52 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001267602-18-000039 · wf-form5_151813394501045.xml · nonDerivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,161 Read SEC document |
| February 15, 2017 Filed Feb 8, 2018 18:52 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001267602-18-000039 · wf-form5_151813394501045.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,661 Read SEC document |
| January 20, 2017 Filed Jan 23, 2017 17:00 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001267602-17-000011 · wf-form4_148520883958351.xml · derivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2027-01-19 F2 · derivative.exercise_date: This option shall vest in forty-eight equal monthly installments beginning on January 20, 2017, provided that the Reporting Person remains continuously employed by the Issuer through each vesting period. Read SEC document |
| January 20, 2017 Filed Jan 23, 2017 17:00 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantCommon Stock | 105,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001267602-17-000011 · wf-form4_148520883958351.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,033 F1 · shares: Represents shares of common stock underlying a restricted stock unit award (RSU). The RSU shall vest in four equal daily installments beginning on January 16, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| October 31, 2016 Filed Feb 13, 2017 17:28 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantCommon Stock | 2,455 | $1.06 | $2,608.44 |
DisclosureSEC source: 0001267602-17-000014 · wf-form5_148702491299210.xml · nonDerivative · entry 5 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,791 F1 · kind: These shares were acquired under the Alimera Sciences, Inc. 2010 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 16:14 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 55,147 | $1.33 Strike: $1.33 | $73,345.51 |
DisclosureSEC source: 0001267602-16-000175 · wf-form4_147638963232428.xml · derivative · entry 3 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,147 shares Expires 2016-10-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Became exercisable with respect to one-quarter (1/4) of the shares of stock which are subject to this option on November 22, 2007 (the "Initial Vesting Date") and with respect to the remainder of the shares in equal increments quarterly over three (3) years beginning on the date three (3) months from the Initial Vesting Date. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 16:14 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Tax withholdingCommon Stock | 48,898 | $1.50 | $73,347.00 |
DisclosureSEC source: 0001267602-16-000175 · wf-form4_147638963232428.xml · nonDerivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,233 F1 · kind: Mr. Myers irrevocably agreed to exercise these options through the "net exercise" method on August 17, 2016. Mr. Myers received 6,249 shares of common stock on a net exercise to purchase 55,147 shares of common stock. Mr. Myers forfeited 48,898 shares of common stock underlying the option in payment of the exercise price, using the closing stock price on October 11, 2016 of $1.50. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 16:14 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Exercise / conversionCommon Stock | 55,147 | $1.33 | $73,345.51 |
DisclosureSEC source: 0001267602-16-000175 · wf-form4_147638963232428.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2016 Filed Feb 13, 2017 17:28 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantCommon Stock | 2,103 | $1.89 | $3,968.36 |
DisclosureSEC source: 0001267602-17-000014 · wf-form5_148702491299210.xml · nonDerivative · entry 4 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,336 F1 · kind: These shares were acquired under the Alimera Sciences, Inc. 2010 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| March 18, 2016 Filed Feb 13, 2017 17:28 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001267602-17-000014 · wf-form5_148702491299210.xml · nonDerivative · entry 3 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,233 Read SEC document |
| February 09, 2016 Filed Feb 13, 2017 17:28 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001267602-17-000014 · wf-form5_148702491299210.xml · nonDerivative · entry 2 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,233 Read SEC document |
| January 12, 2016 Filed Feb 13, 2017 17:28 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001267602-17-000014 · wf-form5_148702491299210.xml · nonDerivative · entry 1 Myers C. Daniel · CIK 0001489533 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,233 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.